相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia
Parsa Mehraban Far et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2022)
Ibrutinib-related uveitis: A report of two severe cases
Marcela Bohn et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2022)
Patterns of use and safety of ibrutinib in real-life practice
Marion Allouchery et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study
Jeff Sharman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
High-grade heart block associated with ibrutinib therapy
Alexander R. Vartanov et al.
HeartRhythm Case Reports (2021)
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
Keisuke Kidoguchi et al.
TURKISH JOURNAL OF HEMATOLOGY (2021)
Panuveitis Presumed Secondary to Ibrutinib Therapy
Sruthi Arepalli et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2021)
Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms
Joris Guyon et al.
JAMA ONCOLOGY (2021)
Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema
Sumeet P. Mirgh et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2020)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor
Melissa F. Adasme et al.
PLOS ONE (2020)
Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase
Lovisa Sandberg et al.
DRUG SAFETY (2020)
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib
Michael Frei et al.
LEUKEMIA & LYMPHOMA (2020)
Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy
Jennifer L. Miatech et al.
CASE REPORTS IN HEMATOLOGY (2020)
Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib
Manuel Saenz-de-Viteri et al.
LEUKEMIA & LYMPHOMA (2019)
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C. Byrd et al.
BLOOD (2019)
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium
Le Jiang et al.
HEART RHYTHM (2019)
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Kristina Busygina et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Bilateral sensorineural hearing loss induced by regorafenib
Jun Cheng et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2019)
Hypertension and incident cardiovascular events following ibrutinib initiation
Tyler Dickerson et al.
BLOOD (2019)
Cardiovascular Toxicities Associated With Ibrutinib
Joe-Elie Salem et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Pharmacoepidemiology, the new paradigm of drug evaluation
Bernard Begaud et al.
THERAPIE (2019)
What is pharmacoepidemiology? Definition, methods, interest and clinical applications
Jean-Louis Montastruc et al.
THERAPIE (2019)
Ibrutinib-associated Serositis in Mantle Cell Lymphoma
Brett A. Styskel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Ibrutinib discontinuation in Waldenstrom macroglobulinemia: Etiologies, outcomes, and IgM rebound
Joshua N. Gustine et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans
Kristina Busygina et al.
BLOOD (2018)
Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase
Julien Mahe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Tilly Varughese et al.
CLINICAL INFECTIOUS DISEASES (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mechanisms of macular edema: Beyond the surface
Alejandra Daruich et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
Avirup Guha et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Empirical estimation of under-reporting in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
Yasser M. Alatawi et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
David Miklos et al.
BLOOD (2017)
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Benjamin L. Lampson et al.
BLOOD (2017)
Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database
Yasuo Oshima et al.
CIRCULATION (2017)
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Darryl P. Leong et al.
BLOOD (2016)
Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases
Suzie Seabroke et al.
DRUG SAFETY (2016)
Electrolyte disorders associated with the use of anticancer drugs
George Liamis et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Sunitinib-induced sudden hearing loss
Kathleen Dekeister et al.
INVESTIGATIONAL NEW DRUGS (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia
Eric Wiedower et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse
Sophie Bernard et al.
BLOOD (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss
Masahiro Shinohara et al.
BONE (2014)
Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review
Olivier Huillard et al.
EUROPEAN JOURNAL OF CANCER (2014)
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
Jason A. Dubovsky et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
Jean-Louis Montastruc et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study
Francisca Gonzalez-Rubio et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Determinants of Under-Reporting of Adverse Drug Reactions A Systematic Review
Elena Lopez-Gonzalez et al.
DRUG SAFETY (2009)
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
Kevin Kelly et al.
TARGETED ONCOLOGY (2009)
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
J. -J. Mourad et al.
ANNALS OF ONCOLOGY (2008)
VigiBase, the WHO Global ICSR Database System: Basic facts
Marie Lindquist
DRUG INFORMATION JOURNAL (2008)
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
SJW Evans et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2001)
分享论文
